Hypertension in pregnancy: diagnosis and management
KEYWORDS: women, hypertension, pre-eclampsia, pregnancy, treatment, birth, committee, recommendations, antihypertensive, amended, risk, blood, evidence, care, gestational

instead of labetalol in the postnatal period. Return to recommendations Risk of recurrence of hypertensive disorders of pregnancy and long-term cardiovascular disease Recommendations 1.10.1 to 1.10.4 Why the committee made the recommendations Long-term follow-up studies of women who have experienced hypertensive disorders during pregnancy showed an increased risk of long-term cardiovascular disease and a higher prevalence of hypertensive disorders in subsequent pregnancies compared with women unaffected by hypertensive disorders. There was no evidence on which interventions could reduce the risk of recurrence of hypertensive disorders of pregnancy or future cardiovascular disease, so the committee made a research recommendation. How the recommendations might affect practice Providing guidance and advice to women on future risks and signposting appropriate care and lifestyle advice may be an additional activity for some healthcare professionals, compared with current practice. Return to recommendations Context Hypertensive disorders during pregnancy affect around 8% to 10% of all pregnant women and can be associated with substantial complications for the woman and the baby. Women can have hypertension before pregnancy or it can be diagnosed in the first 20 weeks (known as chronic hypertension), new onset of hypertension occurring in the second half of pregnancy (gestational hypertension) or new hypertension with
